167 related articles for article (PubMed ID: 16288880)
21. Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.
Zhu GD; Gong J; Gandhi VB; Liu X; Shi Y; Johnson EF; Donawho CK; Ellis PA; Bouska JJ; Osterling DJ; Olson AM; Park C; Luo Y; Shoemaker A; Giranda VL; Penning TD
Bioorg Med Chem; 2012 Aug; 20(15):4635-45. PubMed ID: 22766219
[TBL] [Abstract][Full Text] [Related]
22. Binding mode of novel 1-substituted quinazoline derivatives to poly(ADP-ribose) polymerase-catalytic domain, revealed by X-ray crystal structure analysis of complexes.
Matsumoto K; Kondo K; Ota T; Kawashima A; Kitamura K; Ishida T
Biochim Biophys Acta; 2006 May; 1764(5):913-9. PubMed ID: 16631419
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
Chadha N; Jaggi AS; Silakari O
Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
[TBL] [Abstract][Full Text] [Related]
24. Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.
Giannini G; Battistuzzi G; Vesci L; Milazzo FM; De Paolis F; Barbarino M; Guglielmi MB; Carollo V; Gallo G; Artali R; Dallavalle S
Bioorg Med Chem Lett; 2014 Jan; 24(2):462-6. PubMed ID: 24388690
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Quinazoline-2,4(1
Zhou J; Ji M; Wang X; Zhao H; Cao R; Jin J; Li Y; Chen X; Sheng L; Chen X; Xu B
J Med Chem; 2021 Nov; 64(22):16711-16730. PubMed ID: 34748333
[TBL] [Abstract][Full Text] [Related]
26. Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase.
Hattori K; Kido Y; Yamamoto H; Ishida J; Iwashita A; Mihara K
Bioorg Med Chem Lett; 2007 Oct; 17(20):5577-81. PubMed ID: 17804225
[TBL] [Abstract][Full Text] [Related]
27. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
Griffin RJ; Srinivasan S; Bowman K; Calvert AH; Curtin NJ; Newell DR; Pemberton LC; Golding BT
J Med Chem; 1998 Dec; 41(26):5247-56. PubMed ID: 9857092
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors.
Zhao H; Ji M; Cui G; Zhou J; Lai F; Chen X; Xu B
Bioorg Med Chem; 2017 Aug; 25(15):4045-4054. PubMed ID: 28622906
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of tricyclic derivatives containing a non-aromatic amide as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
Park CH; Chun K; Joe BY; Park JS; Kim YC; Choi JS; Ryu DK; Koh SH; Cho GW; Kim SH; Kim MH
Bioorg Med Chem Lett; 2010 Apr; 20(7):2250-3. PubMed ID: 20189385
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
Karlberg T; Hammarström M; Schütz P; Svensson L; Schüler H
Biochemistry; 2010 Feb; 49(6):1056-8. PubMed ID: 20092359
[TBL] [Abstract][Full Text] [Related]
31. Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1).
Pescatore G; Branca D; Fiore F; Kinzel O; Bufi LL; Muraglia E; Orvieto F; Rowley M; Toniatti C; Torrisi C; Jones P
Bioorg Med Chem Lett; 2010 Feb; 20(3):1094-9. PubMed ID: 20031401
[TBL] [Abstract][Full Text] [Related]
32. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase.
Loh VM; Cockcroft XL; Dillon KJ; Dixon L; Drzewiecki J; Eversley PJ; Gomez S; Hoare J; Kerrigan F; Matthews IT; Menear KA; Martin NM; Newton RF; Paul J; Smith GC; Vile J; Whittle AJ
Bioorg Med Chem Lett; 2005 May; 15(9):2235-8. PubMed ID: 15837300
[TBL] [Abstract][Full Text] [Related]
33. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V
J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors.
Wang LX; Zhou XB; Xiao ML; Jiang N; Liu F; Zhou WX; Wang XK; Zheng ZB; Li S
Bioorg Med Chem Lett; 2014 Aug; 24(16):3739-43. PubMed ID: 25086680
[TBL] [Abstract][Full Text] [Related]
35. Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP).
Griffin RJ; Pemberton LC; Rhodes D; Bleasdale C; Bowman K; Calvert AH; Curtin NJ; Durkacz BW; Newell DR; Porteous JK
Anticancer Drug Des; 1995 Sep; 10(6):507-14. PubMed ID: 7575991
[No Abstract] [Full Text] [Related]
36. Identification and mechanism of action analysis of the new PARP-1 inhibitor 2″-hydroxygenkwanol A.
Dal Piaz F; Ferro P; Vassallo A; Vasaturo M; Forte G; Chini MG; Bifulco G; Tosco A; De Tommasi N
Biochim Biophys Acta; 2015 Sep; 1850(9):1806-14. PubMed ID: 25999161
[TBL] [Abstract][Full Text] [Related]
37. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
38. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of pyridazino[3,4,5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors.
Wang J; Tan H; Sun Q; Ge Z; Wang X; Wang Y; Li R
Bioorg Med Chem Lett; 2015 Jun; 25(11):2340-4. PubMed ID: 25899312
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of poly(adenosine diphosphate-ribose) polymerase using quinazolinone nucleus.
Hemalatha K; Madhumitha G
Appl Microbiol Biotechnol; 2016 Sep; 100(18):7799-814. PubMed ID: 27470142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
